🔴 Iovance Biotherapeutics is trading 4.37% down today as biotech and broader markets sell off

Iovance Biotherapeutics is trading at $8.32, down 4.37%, alongside a biotech sector sell-off.

• XBI fell 5.19% during the session, while sharp declines in major indexes reflected broader risk-off pressure on growth stocks.
• Iovance reported record third-quarter revenue of $121.5 million, beating estimates, and reaffirmed full-year revenue guidance of $410–$420 million. No company-specific negative catalyst was identified; the positive report does not explain the decline.